Ibere Pharmaceuticals Overview
Ibere Pharmaceuticals (IBER) has a ROE of 10.08%, above the sector sector average of -4.11%.
Get informed when a big investor buys or sells
+ Follow10.08%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for IBER is 10.08%. That is above the sector sector average of -4.11%. Investors often review this figure alongside Ibere Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, IBER currently prints 10.08% for ROE, while the sector average sits near -4.11%. That is roughly 345.4% above the sector mean. Large gaps often invite a closer look at Ibere Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively Ibere Pharmaceuticals converts resources into returns. At 10.08%, IBER may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting IBER's ROE (10.08%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
